Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients

Trial Identifier: D6570C00001
Sponsor: AstraZeneca
Menarini (Co-Funder)
NCTID:: NCT02424344
Start Date: April 2015
Primary Completion Date: July 2016
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, BC Vancouver, BC, Canada, V5Z 1M9
Canada, ON Hamilton, ON, Canada, L8N 3Z5
Canada, ON Kingston, ON, Canada, K7L 2V7
Canada, QC Sainte Foy, QC, Canada, G1V 4G5
Canada, SK Saskatoon, SK, Canada, S7N 0W8
Germany Berlin, Germany, 10787
Germany Berlin, Germany, 10117
Germany Berlin, Germany, 10717
Germany Berlin, Germany, 13086
Germany Berlin, Germany, 10969
Germany Bonn, Germany, 53123
Germany Dortmund, Germany, 44263
Germany Frankfurt, Germany, 60596
Germany Freiburg, Germany, 79106
Germany Großhansdorf, Germany, 22927
Germany Hamburg, Germany, 20354
Germany Hamburg, Germany, 20253
Germany Hannover, Germany, 30173
Germany Jena, Germany, 7740
Germany Lübeck, Germany, 23552
Germany München, Germany, 80331
Germany Wiesbaden, Germany, 65187
Germany Witten, Germany, 58452
Hungary Budapest, Hungary, 1125
Hungary Debrecen, Hungary
Hungary Deszk, Hungary, 6772
Hungary Mátraháza, Hungary, 3233
Hungary Nyíregyháza, Hungary, 4400
Hungary Törökbálint, Hungary, 2045
Italy Cassano Delle Murge, Italy, 70020
Italy NAPOLI, Italy, 80131
Italy Parma, Italy, 43125
Italy Pisa, Italy, 56124
Italy Telese Terme, Italy, 82037
Spain Alicante, Spain, 03004
Spain Cáceres, Spain, 10003
Spain Madrid, Spain, 28046
Spain Valencia, Spain, 46010